Skip to content

ID · Infusion & OPAT

Running an Infusion and OPAT Business Alongside a Consult Practice

In infectious disease, operations means running an infusion and OPAT business alongside a consultative clinical practice. This section covers the constraints that determine whether that combination works: OPAT economics, infusion capacity, staffing and the referral-to-first-dose pathway.

An IV pole and infusion bag standing beside an armchair in a domestic living room.

OPAT

Who pays, and on which days

The defining structural fact of US OPAT is a coverage asymmetry that determines site of care more than clinical factors do.

Published work in the infectious disease literature has documented that Medicare does not reimburse home infusion of antimicrobials as commercial insurers generally do, with reimbursement available principally for days on which a health professional attends the home. Research on OPAT delivery has reported that roughly a quarter of Medicare OPAT patients received home infusion compared with around 60% of patients with other insurance — a coverage effect rather than a clinical one.

The operational consequence: your program needs at least three pathways — home infusion, outpatient infusion centre or suite, and skilled nursing facility — and an intake process that determines the pathway before the therapy plan is built.

Underneath sits the uncompensated coordination problem. Authorisation, vascular access, monitoring, weekly review and complication response are substantial skilled work that generates few billable events. If it is not billed, contracted or explicitly staffed, the practice is subsidising it.

Worth holding on to

Determine coverage at intake
A plan built before coverage is understood usually has to be rebuilt.
Fund the coordinator
Programs degrade under volume when coordination is distributed across people with other jobs.
Contract the hospital value
Avoided inpatient days accrue to the institution; that is a legitimate basis for an agreement.

Infusion capacity

Chairs, chair-turns and the real constraint

Effective capacity is chairs times hours divided by chair time times utilisation — and then limited by nursing.

Chair time is not infusion time: it includes access, pre-medication, the infusion, observation and turnover. Utilisation is never complete, because infusion durations do not tile neatly into a working day.

Then apply the binding constraint. Safe concurrent-patient ratios for infusion nursing usually determine throughput before chair count does. A suite with eight chairs and staffing for four concurrent patients is a four-chair business paying rent on eight.

Worth holding on to

Model the turn, not the drip
Access, observation and turnover are chair-occupying time.
Test at lower utilisation
If the project only works at optimistic fill, it is underwriting two risks at once.
Don't rest the case on drug spread alone
Administration, associated encounters and retained referrals belong in the model.

Staffing

The pharmacist, the coordinator and the cold chain

ID staffing looks different because the ancillary business is pharmaceutical rather than mechanical.

Infusion nursing sets the capacity ceiling. Pharmacist involvement — employed or contracted — covers clinical review, dosing, compounding oversight, storage and handling, and stewardship support. The OPAT coordinator handles referral intake, verification, access arrangement, laboratory scheduling and complication triage.

The coordinator is the role most often left unfunded, and surveyed OPAT programs consistently report coordination and communication among their central challenges. Fund it, then identify explicitly what pays for it.

APP scope, supervision and billing arrangements are set by state law and modified by payer policy. Verify what applies to your practice before designing the role or modelling its contribution.

Underneath all of it sits the physical regime a drug-heavy practice is obliged to run: validated cold-chain storage with alarming, a compounding environment meeting professional and state pharmacy requirements, emergency medications and drilled reaction protocols, and monthly inventory reconciliation against administered doses. None of it is optional, so omitting it from the business case does not make a suite cheaper — only mis-costed.

Worth holding on to

Build from the week
Consults, clinic sessions, chair-hours, patients under monitoring, authorisation volume, committee obligations.
Staff the authorisation function
In drug-heavy practice this is a position, not a task.
Cold chain is a financial control
Continuous temperature monitoring with alarming, a written excursion response, and back-up power. One lost inventory costs more than the equipment.
Emergency readiness is a process
A written reaction protocol, drilled staff, a transfer plan and documented review — not a crash cart in a cupboard.
Cross-train deliberately
Concentrated pathway knowledge is an operational risk with a financial expression.

Workflow

Referral to first dose

The single interval that captures coverage, authorisation, access, pharmacy, nursing and communication at once.

Timestamp each handoff for twenty consecutive referrals: triage, coverage determination, authorisation, vascular access, pharmacy readiness, nursing scheduling, first dose. The step with the longest median is your capacity constraint; the step with the widest variance is your reliability problem. They are usually different.

Report the median and the ninetieth percentile. A good median with a long tail means a small group of patients waits a clinically meaningful time — and those are the patients most likely to deteriorate or be lost to the program.

Worth holding on to

Coverage first, always
The intake sequencing change that removes the most rework.
Watch the tail
The worst decile is where the clinical risk concentrates.